Cedrik M. Britten
Chief Tech/Sci/R&D Officer bei IMMATICS N.V.
Vermögen: 2 Mio $ am 30.04.2024
Aktive Positionen von Cedrik M. Britten
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IMMATICS N.V. | Chief Tech/Sci/R&D Officer | 01.06.2020 | - |
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Chief Tech/Sci/R&D Officer | 01.06.2020 | - |
Karriereverlauf von Cedrik M. Britten
Ehemalige bekannte Positionen von Cedrik M. Britten
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
GSK PLC | Corporate Officer/Principal | 01.02.2015 | 01.05.2020 |
BioNTech RNA Pharmaceuticals GmbH
BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The private company is based in Mainz, Germany. | Chief Tech/Sci/R&D Officer | 01.06.2010 | 01.01.2015 |
Ausbildung von Cedrik M. Britten
The Johannes Gutenberg University of Mainz | Doctorate Degree |
Statistik
International
Deutschland | 5 |
Vereinigtes Königreich | 2 |
Operativ
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 1 |
Doctorate Degree | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
GSK PLC | Health Technology |
IMMATICS N.V. | Health Technology |
Private Unternehmen | 2 |
---|---|
Immatics Biotechnologies GmbH
Immatics Biotechnologies GmbH Pharmaceuticals: MajorHealth Technology Immatics Biotechnologies GmbH operates as a biopharmaceutical company that develops anti-cancer immunotherapy products. The firm specializes in the discovery and development of immunotherapy products against cancer. It develops IMA901, a combination of multiple tumor-associated peptides (TUMAPs) for the treatment of renal cell carcinoma. The company was founded by Harpreet Singh, Toni Weinschenk, Niels Emmerich, Hans Georg Rammensee, Hansjörg Schild, and Peter Brossart in 2000 and is headquartered in Tübingen, Germany. | Health Technology |
BioNTech RNA Pharmaceuticals GmbH
BioNTech RNA Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Part of BioNTech SE, BioNTech RNA Pharmaceuticals GmbH develops immunotherapies to revolutionize the treatment of cancer and other diseases. The private company is based in Mainz, Germany. | Health Technology |
- Börse
- Insiders
- Cedrik M. Britten
- Erfahrung